Univeristy and government led innovation fails---industry is key to new treatments
Thomas Stossel 17, is the Director of the Translational Medicine Division and Senior Physician in Hematology at Brigham & Women's Hospital, Harvard Medical School. 1/4/17, “Removing barriers to medical innovation” http://www.aei.org/publication/912939/
Enormous improvements in human health have taken place over the last half-century. Americans live, on average, a decade longer. The most prevalent cause of mortality in the United States — cardiovascular disease, which causes heart attacks and strokes — has decreased by over 50%. Cancer, the number-two cause, has become far more treatable, and cancer mortality rates have plummeted in recent years. A few decades ago, it was common to see individuals whom arthritis had deformed and condemned to immobility and chronic pain. Now, such victims are uncommon. Mental-hospital wards that used to house patients with intractable psychoses and depression either sit empty or have been repurposed. The outbreak of the HIV/AIDS epidemic in the 1980s elicited apocalyptic predictions that it would bankrupt the health-care system. But within two decades, many HIV-infected individuals were living normal, albeit medicated lives.
The driving force behind these remarkable improvements is unquestionably medical innovation: new technologies including medications, medical devices, and improved medical procedures. But most people are unaware of who or what deserves our gratitude for these advances.
In a 2015 commentary in the New York Times about medical innovation, Nobel Laureate economist Joseph Stiglitz wrote, “As it is, most of the important innovations come out of our universities and research centers, like the National Institutes of Health, funded by government and foundations.” If asked, most people would agree: The credit for medical innovation belongs to research performed at universities and in non-profit research institutes. And, for more than half a century, the American government has provided most of the funding for such research, creating what might usefully be termed a “government-academic biomedical complex.”
Most people are aware that universities and government- and foundation-funded research centers do not actually manufacture innovative products. But they conclude, based on such statements from authorities like Stiglitz, that the private firms that do accomplish this task do so simply by exploiting the discoveries arising from universities and research centers. This conclusion, which is false, is one manifestation of what I have called “the pharmaphobia narrative”: a set of ideas that demonize the private medical-products industry, and that is promulgated by the principal beneficiaries of the relationship between the government and research institutions, such as university officials and medical-journal editors.
Powerful cultural and economic forces in universities and research institutes combine with the pharmaphobia narrative to make this government-academic biomedical complex not just relatively inefficient for achieving medical innovation but even counterproductive to it. It is time to reduce the power of this complex to dictate the direction of research and build a complementary partnership between academic institutions and private industry. A private-academic partnership would allocate resources and talent far more effectively, paving the way for further life-enhancing medical innovations.
INNOVATION EVOLVES
The history of medical innovation can be divided into three eras. The first consists of the centuries during which knowledge potentially relevant for medical treatments slowly accumulated, through the study of human anatomy, the realization that blood circulates, and other insights. This information, however, did not stem the practice of useless and harmful bleeding and purging therapies, which were based on ancient theories and legends. The more recent adoption of effective measures such as antisepsis and anesthesia also had to overcome stubborn resistance from the medical profession.
The second era of medical innovations came in the 19th century with the establishment of universities and independent institutes in Europe, and subsequently in North America. Innovations originating from these institutions included a wide variety of revolutionary treatments: the identification and potential eradication of disease-spreading insects; effective treatments of infectious disease with antitoxins and antibiotics; vaccines to prevent diphtheria, pertussis, tetanus, and polio; anticoagulants (“blood thinners”); and vitamin and hormone-replacement therapies.
In this second innovation era, medical advances did in fact largely arise in universities and research institutes. Private industry’s role was to provide manufacturing capabilities that enabled the discoveries to benefit patients, and it was the principal source of the chemical compounds that clinicians — often in academic settings — tested for therapeutic effects.
The essential contributions of science in general and medical innovation in particular to the Allied victory in World War II ushered in the third and current era of innovation. Franklin Roosevelt’s science advisor, Vannevar Bush, called in 1945 for a sharply increased federal investment in research. Bush’s entreaty, entitled “Science: The Endless Frontier,” emphasized the importance of basic research unlinked to practical ends as the best route to innovation. The result of Bush’s effort and impassioned lobbying by medical academics was that the federal government markedly increased its spending on the National Institutes of Health, such that it became the major source of medical-research funding in the United States. Its “intramural” facility in Bethesda, Maryland, emerged as the country’s largest research institute. For decades, Congress allocated generous and growing funds to the NIH that enabled it to provide many research grants to universities. As a result, universities expanded their laboratory facilities and research faculties — and the government-academic biomedical complex, or GABC, was born.
Truth be told, however, in this era private industry, rather than the GABC, has progressively become the dominant source of new medical products. By 1990, corporate investment in medical research had exceeded that of the NIH, and it is now over twice as large. Three separate analyses concluded that 85% of the drugs approved by the FDA since 1988 arose solely from research and development performed within the industry.
An important fact to remember about medical innovation is that, unlike engineering advances informed by physics and chemistry, it relies on the far more uncertain underpinning of biology. Although insufficient information is one reason for this uncertainty, the dominant problem is the biological variability that evolution has programmed into us. Highly mutable micro-organisms dominate our world and use the components of our bodies to colonize and sicken us. If our responses were static and predictable, these invaders would have eliminated our species eons ago. The liability of this unpredictability is that drugs that seem promising in the laboratory or in inbred animals more often than not fail in clinical trials. As a result, the basic science discoveries championed by Vannevar Bush, though extremely valuable in some ways, are not reliable or straightforward guarantees of medical innovation. Regardless, the GABC continues to pour money into the pursuit of basic science, often in the name of medical innovation, for a number of cultural and economic reasons.